Amylyx Pharmaceuticals (AMLX) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $26.34, -4.74% vs the prior close of $27.65.
- Volume 1.15M shares, 0.5x its 50-day average (light).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
AMLX slides 4.7% to $26.34, a 1-month low. Closed at $26.34, -4.74% vs the prior close of $27.65. Day range $26.20–$27.65, opened at $27.65.
AMLX daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — AMLX slides 4.7% to $26.34, a 1-month low
- Closed at $26.34, -4.74% vs the prior close of $27.65. Day range $26.20–$27.65, opened at $27.65.
- Volume was 1.15M shares, 0.5x its 50-day average of 2.40M — lighter than usual.
- Price is -14.2% vs its 50-day average ($30.68) and +36.6% vs its 200-day average ($19.28).
- 52-week range $10.83–$41.14; today's close sits at 51% of that range, 36.0% below the 52-week high.
Oct 15, 2026 — AMLX rises 2.3% to $27.65
- Closed at $27.65, +2.29% vs the prior close of $27.03. Day range $27.45–$28.34, opened at $27.68.
- Volume was 882.50K shares, 0.4x its 50-day average of 2.42M — lighter than usual.
- Price is -9.8% vs its 50-day average ($30.64) and +44.0% vs its 200-day average ($19.20).
- 52-week range $10.83–$41.14; today's close sits at 55% of that range, 32.8% below the 52-week high.
Oct 14, 2026 — AMLX rises 0.7% to $27.03
- Closed at $27.03, +0.67% vs the prior close of $26.85. Day range $26.46–$27.77, opened at $26.80.
- Volume was 1.17M shares, 0.5x its 50-day average of 2.46M — lighter than usual.
- Price is -11.4% vs its 50-day average ($30.52) and +41.3% vs its 200-day average ($19.13).
- 52-week range $10.83–$41.14; today's close sits at 53% of that range, 34.3% below the 52-week high.
Oct 13, 2026 — AMLX dips 2.3% to $26.85, a 1-month low
- Closed at $26.85, -2.29% vs the prior close of $27.48. Day range $26.80–$27.69, opened at $27.49.
- Volume was 1.06M shares, 0.4x its 50-day average of 2.47M — lighter than usual.
- Price is -11.7% vs its 50-day average ($30.42) and +40.9% vs its 200-day average ($19.05).
- 52-week range $10.83–$41.14; today's close sits at 53% of that range, 34.7% below the 52-week high.
Oct 12, 2026 — AMLX dips 2.3% to $27.48
- Closed at $27.48, -2.35% vs the prior close of $28.14. Day range $27.40–$28.49, opened at $28.04.
- Volume was 1.11M shares, 0.4x its 50-day average of 2.49M — lighter than usual.
- Price is -9.3% vs its 50-day average ($30.29) and +44.8% vs its 200-day average ($18.98).
- 52-week range $10.83–$41.14; today's close sits at 55% of that range, 33.2% below the 52-week high.
Oct 9, 2026 — AMLX jumps 3.5% to $28.14
- Closed at $28.14, +3.46% vs the prior close of $27.20. Day range $26.94–$28.60, opened at $27.32.
- Volume was 1.47M shares, 0.6x its 50-day average of 2.53M — lighter than usual.
- Price is -6.6% vs its 50-day average ($30.14) and +48.8% vs its 200-day average ($18.91).
- 52-week range $10.83–$41.14; today's close sits at 57% of that range, 31.6% below the 52-week high.
Oct 8, 2026 — AMLX dips 0.8% to $27.20, a 1-month low
- Closed at $27.20, -0.84% vs the prior close of $27.43. Day range $26.04–$27.53, opened at $27.01.
- Volume was 2.62M shares, 1.0x its 50-day average of 2.52M.
- Price is -9.3% vs its 50-day average ($30.00) and +44.5% vs its 200-day average ($18.83).
- 52-week range $10.83–$41.14; today's close sits at 54% of that range, 33.9% below the 52-week high.
Oct 7, 2026 — AMLX dips 2.2% to $27.43, a 1-month low
- Closed at $27.43, -2.18% vs the prior close of $28.04. Day range $27.21–$28.46, opened at $27.72.
- Volume was 2.06M shares, 0.8x its 50-day average of 2.55M.
- Price is -8.1% vs its 50-day average ($29.85) and +46.3% vs its 200-day average ($18.75).
- 52-week range $10.83–$41.14; today's close sits at 55% of that range, 33.3% below the 52-week high.
Oct 6, 2026 — AMLX rises 0.9% to $28.04
- Closed at $28.04, +0.94% vs the prior close of $27.78. Day range $27.00–$28.50, opened at $27.97.
- Volume was 1.28M shares, 0.5x its 50-day average of 2.57M — lighter than usual.
- Price is -5.6% vs its 50-day average ($29.69) and +50.2% vs its 200-day average ($18.67).
- 52-week range $10.83–$41.14; today's close sits at 57% of that range, 31.8% below the 52-week high.
Oct 5, 2026 — AMLX ends flat (-0.0%) to $27.78, a 1-month low, 5 down days in a row
- Closed at $27.78, -0.04% vs the prior close of $27.79. Day range $27.34–$28.09, opened at $27.92.
- Volume was 940.90K shares, 0.4x its 50-day average of 2.59M — lighter than usual.
- Price is -5.9% vs its 50-day average ($29.52) and +49.4% vs its 200-day average ($18.59).
- 52-week range $10.83–$41.14; today's close sits at 56% of that range, 32.5% below the 52-week high.
- That makes 5 straight losses.
Oct 2, 2026 — AMLX dips 1.0% to $27.79, a 1-month low, 4 down days in a row
- Closed at $27.79, -1.03% vs the prior close of $28.08. Day range $27.64–$28.81, opened at $28.50.
- Volume was 912.40K shares, 0.4x its 50-day average of 2.58M — lighter than usual.
- Price is -5.3% vs its 50-day average ($29.33) and +50.1% vs its 200-day average ($18.52).
- 52-week range $10.83–$41.14; today's close sits at 56% of that range, 32.5% below the 52-week high.
- That makes 4 straight losses.
AMLX latest news & SEC filings
Every SEC filing by or about AMLX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 7, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Milne George M Jr sold 30,000 shares at $27.70 (≈$830.90K) on Oct 5, 2026; now holds 782,881
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 5, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 14, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 14, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Frates James M sold 9,768 shares at $32.27 (≈$315.21K) on Sep 10, 2026
- Frates James M sold 1,042 shares at $33.23 (≈$34.63K) on Sep 10, 2026
- Frates James M sold 9,768 shares at $32.27 (≈$315.21K) on Sep 10, 2026
- Frates James M sold 1,042 shares at $33.23 (≈$34.63K) on Sep 10, 2026
- Frates James M sold 9,768 shares at $32.27 (≈$315.21K) on Sep 10, 2026
- Frates James M sold 1,042 shares at $33.23 (≈$34.63K) on Sep 10, 2026
- …plus 2 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 14, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Mazzariello Gina sold 9,525 shares at $32.46 (≈$309.18K) on Sep 10, 2026
- Mazzariello Gina sold 11 shares at $33.34 (≈$367) on Sep 10, 2026
- Mazzariello Gina sold 9,525 shares at $32.46 (≈$309.18K) on Sep 10, 2026
- Mazzariello Gina sold 11 shares at $33.34 (≈$367) on Sep 10, 2026
- Mazzariello Gina sold 9,525 shares at $32.46 (≈$309.18K) on Sep 10, 2026
- Mazzariello Gina sold 11 shares at $33.34 (≈$367) on Sep 10, 2026
- …plus 2 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 14, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Klee Justin B. sold 1,439 shares at $33.16 (≈$47.72K) on Sep 10, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 8, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
Aug 20, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
Aug 20, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 18, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 18, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Aug 18, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$43.42M (prior year -$41.44M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.39 (prior year -$0.46) (loss narrowed vs Jun 30, 2025)
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Things to know before you trade AMLX
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Mar 3, 2026, Nov 6, 2025. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.05% (largest 7.3%).
- Liquidity: about 1.32M shares (≈$34.82M) trade per day on average.
- 52-week position: $26.34 vs a range of $10.83–$41.14 (51% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Gina Mazzariello sold 9,525 shares on Sep 10, 2026.
- Latest filings: 8-K Sep 8, 2026; 8-K Aug 20, 2026; 8-K Aug 18, 2026.
- Share count: 111.42M shares outstanding (Jul 27, 2026), +25.0% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
AMLX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 27.65 | 27.65 | 26.20 | 26.34 | 1.15M |
| Oct 15, 2026 | 27.68 | 28.34 | 27.45 | 27.65 | 882.50K |
| Oct 14, 2026 | 26.80 | 27.77 | 26.46 | 27.03 | 1.17M |
| Oct 13, 2026 | 27.49 | 27.69 | 26.80 | 26.85 | 1.06M |
| Oct 12, 2026 | 28.04 | 28.49 | 27.40 | 27.48 | 1.11M |
| Oct 9, 2026 | 27.32 | 28.60 | 26.94 | 28.14 | 1.47M |
| Oct 8, 2026 | 27.01 | 27.53 | 26.04 | 27.20 | 2.62M |
| Oct 7, 2026 | 27.72 | 28.46 | 27.21 | 27.43 | 2.06M |
| Oct 6, 2026 | 27.97 | 28.50 | 27.00 | 28.04 | 1.28M |
| Oct 5, 2026 | 27.92 | 28.09 | 27.34 | 27.78 | 940.90K |
| Oct 2, 2026 | 28.50 | 28.81 | 27.64 | 27.79 | 912.40K |
| Oct 1, 2026 | 28.62 | 29.28 | 27.55 | 28.08 | 1.35M |
| Sep 30, 2026 | 29.47 | 29.62 | 28.64 | 29.10 | 1.31M |
| Sep 29, 2026 | 29.87 | 30.10 | 28.99 | 29.28 | 1.18M |
| Sep 28, 2026 | 29.10 | 30.14 | 28.71 | 29.85 | 1.02M |
| Sep 25, 2026 | 30.28 | 30.70 | 29.47 | 29.49 | 1.29M |
| Sep 24, 2026 | 30.73 | 31.00 | 29.83 | 30.14 | 1.42M |
| Sep 23, 2026 | 32.88 | 33.02 | 30.53 | 30.60 | 1.82M |
| Sep 22, 2026 | 32.52 | 33.19 | 32.25 | 33.00 | 1.38M |
| Sep 21, 2026 | 32.55 | 33.16 | 31.90 | 32.39 | 1.01M |
About Amylyx Pharmaceuticals
Amylyx Pharmaceuticals (AMLX) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in CAMBRIDGE, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1658551.
AMLX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Joshua B Cohen | Co-Chief Executive Officer | Sep 14, 2026 |
| Paul R. Fonteyne | Director | Jun 8, 2026 |
| Karen Firestone | Director | Sep 2, 2026 |
| Justin B. Klee | Co-Chief Executive Officer | Sep 14, 2026 |
| George M Jr Milne | Director | Jun 8, 2026 |
| Daphne Quimi | Director | Jun 8, 2026 |
| Bernhardt G Zeiher | Director | Jun 8, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Camille L Bedrosian | Chief Medical Officer | Sep 14, 2026 |
| Joshua B Cohen | Co-Chief Executive Officer | Sep 14, 2026 |
| James M Frates | Chief Financial Officer | Sep 14, 2026 |
| Justin B. Klee | Co-Chief Executive Officer | Sep 14, 2026 |
| Gina Mazzariello | Chief Legal Officer | Sep 14, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 10, 2026 | Gina Mazzariello | Sale | 9,525 | $32.46 |
| Sep 10, 2026 | Gina Mazzariello | Sale | 11 | $33.34 |
| Sep 10, 2026 | Gina Mazzariello | Sale | 9,525 | $32.46 |
| Sep 10, 2026 | Gina Mazzariello | Sale | 11 | $33.34 |
| Sep 10, 2026 | Gina Mazzariello | Sale | 9,525 | $32.46 |
| Sep 10, 2026 | Gina Mazzariello | Sale | 11 | $33.34 |
| Sep 10, 2026 | Gina Mazzariello | Sale | 9,525 | $32.46 |
| Sep 10, 2026 | Gina Mazzariello | Sale | 11 | $33.34 |
| Sep 10, 2026 | James M Frates | Sale | 9,768 | $32.27 |
| Sep 10, 2026 | James M Frates | Sale | 1,042 | $33.23 |
| Sep 10, 2026 | James M Frates | Sale | 9,768 | $32.27 |
| Sep 10, 2026 | James M Frates | Sale | 1,042 | $33.23 |
| Sep 10, 2026 | James M Frates | Sale | 9,768 | $32.27 |
| Sep 10, 2026 | James M Frates | Sale | 1,042 | $33.23 |
| Sep 10, 2026 | James M Frates | Sale | 9,768 | $32.27 |
AMLX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $0 | $-144.74M | -1.53 | $-123.34M |
| Dec 31, 2024 | $87.37M | $-301.74M | -4.43 | $-167.65M |
| Dec 31, 2023 | $380.79M | $49.27M | 0.70 | $11.92M |
| Dec 31, 2022 | $22.23M | $-198.38M | -3.39 | $-179.87M |
| Dec 31, 2021 | — | $-87.93M | -13.35 | $-74.80M |
Latest balance sheet: total assets $264.56M, total liabilities $25.40M, cash $49.33M (as of Jun 30, 2026).
AMLX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $24.19 |
| May 7, 2026 | 8-K Item 2.02 (results) | $15.20 |
| Mar 3, 2026 | 8-K Item 2.02 (results) | $14.11 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $12.46 |
| Aug 7, 2025 | 8-K Item 2.02 (results) | $7.84 |
| May 8, 2025 | 8-K Item 2.02 (results) | $4.58 |
| Mar 4, 2025 | 8-K Item 2.02 (results) | $3.01 |
| Nov 7, 2024 | 8-K Item 2.02 (results) | $6.54 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| May 9, 2024 | 8-K Item 2.02 (results) | — |
| Feb 22, 2024 | 8-K Item 2.02 (results) | — |
| Nov 9, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on AMLX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.